. 2016 Jul 18;7(3):139–145. doi: 10.15171/jlms.2016.24

Table 3 . Clinical Parameters (mm, Mean ± SD) at Baseline, 1.5 and 3 Months After Therapy in Case and Control Groups .

Parameters	Baseline	After 1.5 Months	The Difference Baseline to 1.5 Months	After 3 Months	The Difference 1.5 to 3 Months	The Dfference Baseline to 3 Months
PPD
Case	5.36 ± 1.13	3.75 ± 0.9	1.6 ± 0.61^a	3.13 ± 0.54	1.6 ± 0.61^a	2.2 ± 0.84^a
Control	5.08 ± 1.47	5.09 ± 1.5	0.01 ± 0.9	5.08 ± 1.5	0.01 ± 0.9	0
CAL^b
Case^c	7.36 ± 1.57	5.57 ± 1.09	1.79 ± 0.96^a	4.79 ± 1.36	0.78 ± 0.6^a	2.57 ± 0.88^d
Control	7.16 ± 1.4	7.17 ± 1.4	0.01 ± 0.07	7.18 ± 1.4	0.01 ± 0.07	0.02 ± 0.07
MR
Case	2 ± 1.76	1.9 ± 1.59	0.1 ± 0.32	1.9 ± 1.63	0	0.1 ± 0.32
Control	2.2 ± 1.68	2.2 ± 1.68	0	2.2 ± 1.68	0	0

^aStatistically significant differences.

^bSignificant differences between groups were analyzed using Mann-Whitney test.

^cSignificant differences intra-groups were analyzed using Wilcoxon signed-rank test.

^dSignificant differences during three-time point were analyzed using Friedman test.